Generic maker hits back at Novartis stay bid

06-10-2022

Staff Writer

Generic maker hits back at Novartis stay bid

Taljat David / Shutterstock.com

HEC claims the delay would buy Novartis months of “unjustified monopoly profits” | Response says the Swiss big pharma company makes $3.8m a day from multiple sclerosis drug at issue.


Novartis, Federal Circuit, patent, patent infringement, HEC Pharm, Gilenya, generics, multiple sclerosis, Supreme Court

LSIPR